story of the week
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The New England Journal of Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
N. Engl. J. Med 2019 Feb 21;380(8)741-751, A Bardia, IA Mayer, LT Vahdat, SM Tolaney, SJ Isakoff, JR Diamond, J O'Shaughnessy, RL Moroose, AD Santin, VG Abramson, NC Shah, HS Rugo, DM Goldenberg, AM Sweidan, R Iannone, S Washkowitz, RM Sharkey, WA Wegener, K KalinskyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.